The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018 as amended by virtue of the Market Abuse (Amendment) (EU Exit) Regulations 2019. Upon publication of this announcement, this inside information is now considered to be in the public domain. DXS INTERNATIONAL PLC (AQSE: DXSP) ANNUAL RESULTS for the year ended 30 April 2026 The Board of DXS International plc (AQSE: DXSP)(“the Company”), the AQSE Growth Market quoted healthcare information and digital clinical decision support systems provider, is pleased to announce its audited Final Results for the year ended 30 April 2026. Financial HighlightsProfit of £61,839 (2025: loss of £94,750). Revenue decreased...

ABC arbitrage HY 2026 Consolidated Results¹: €26.0 m (+47%) Annualised ROE 2026: 27.4% | EPS HY 2026: €0.44The Board of Directors of ABC arbitrage, presided by the Chairman Dominique Ceolin, met on September 17, 2026 to approve the consolidated financial statements for the first semester 2026¹. Key financial data are as follows:In millions of euros June 30, 2026 IFRS June 30, 2025 IFRS Var % Dec. 31, 2025 IFRSCurrent operating income €51.0 m €36.5 m 40% €59.7 mNet income €26.0 m €17.7 m 47% €25.1 mEarnings per share (EPS) €0.44 €0.30 47% €0.42Return on equity (ROE) 27.4 % 20.3 % 35% 14.8 %Equity €189.2 m €174.4 m 8% €169.6 mContext – In the first half of 2026, the progressive increase in volatility culminated in a significant period of stress, without, however, reaching the levels recorded in April 2025. Over the...

Jemperli global net sales of $644 million (£480 million) for the six months ended June 30, 2026, representing 34% year-over-year growth Positive interim results from the pivotal AZUR-1 trial of Jemperli in untreated stage II/III dMMR/MSI-H locally advanced rectal cancer announced in July; FDA PDUFA action date of February 2027 with eligibility for expedited review through the National Priority Voucher program, which could result in an earlier FDA decision Litigation with GSK and Tesaro: trial held in July; post-trial hearing scheduled for October 20, 2026, with a judgement anticipated in Q4 2026 or Q1 2027SAN DIEGO, Sept. 21, 2026 (GLOBE NEWSWIRE) — AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with Tesaro, a GSK company, and Quimilza (imsidolimab) with Vanda, today reported...

Gross margin expands to 68%; G&A down 25%; Company advances capital restructuring SÃO PAULO, Sept. 21, 2026 (GLOBE NEWSWIRE) — NVNI Group Limited (NASDAQ: NVNI) (“Nuvini” or the “Company”), an acquirer and operator of B2B SaaS companies in Brazil and Latin America, today reported unaudited results for the six months ended June 30, 2026, as filed with the U.S. Securities and Exchange Commission on Form 6-K. FIRST HALF 2026 HIGHLIGHTS Compared with the six months ended June 30, 2025; amounts in Brazilian reais.Net operating revenue of R$97.4 million, essentially flat; platform subscription revenue of R$90.5 million, 93% of total revenue Gross profit of R$66.3 million, up 7.0%; gross margin expanded 500 basis points to 68.1% in first half 2026 General and administrative expenses reduced 24.6% to R$31.6 million; total personnel...

Revenues rose 36.6% year over year, mainly driven by higher average selling prices AI infrastructure and liquid cooling continue to gain strategic importance, with large-volume customer orders secured subsequent to the first half of 2026SHENZHEN, China, Sept. 21, 2026 (GLOBE NEWSWIRE) — ZJK Industrial Co., Ltd. (NASDAQ: ZJK) (“ZJK” or the “Company”), a high-tech precision parts and hardware manufacturer serving artificial intelligence (AI) infrastructure, consumer electronics, electric vehicles, aerospace, and other smart technologies, today announced its unaudited financial results for the six months ended June 30, 2026. First Half of Fiscal Year 2026 Financial HighlightsRevenues were US$33.74 million for the first half of 2026, an increase of 36.60% from US$24.70 million for the same period of 2025. Gross profit was US$14.29 million...

~ Adding a Second Metal Endowment at the Steller Project~ VANCOUVER, British Columbia, Sept. 21, 2026 (GLOBE NEWSWIRE) — Blue Jay Gold Corp. (TSXV: JAY) (OTCQB: JAYGF) (FSE: JAY) (“Blue Jay” or the “Company”), today reported results from the metallurgical test program on mineralization from the Becker-Cochran antimony occurrence at its Steller Gold Project (“Steller” or the “Project”) in southern Yukon. Our maiden test work at ALS Metallurgical Laboratories in Kamloops, British Columbia delivered a flowsheet design producing a 67% antimony (“Sb”) concentrate at a 94% recovery. Roughly 50 kg of the concentrate is now being converted into finished antimony products by three North American processing groups who are looking to secure access to long-term supply, with first products expected in the coming weeks. Our test does not end...

Press release Societe Generale presents an ambitious strategic roadmap supportedby disciplined execution Paris, 21 September 2026 A new phase of disciplined, profitable and value-creating growthSociete Generale presents its strategic roadmap for 2029, opening a new development phase after the successful transformation initiated in 2023. With a simplified model, an improved risk profile, increased discipline in capital allocation, and a substantially improved financial performance, the Group is now entering a new stage of value creation based on four main priorities:Decrease further our cost base: the Group will pursue its cost reduction efforts, continuing the structural measures successfully undertaken in recent years, by relying on traditional levers of simplification, operational efficiency and technological transformation, as well...

WUXI, China, Sept. 18, 2026 (GLOBE NEWSWIRE) — LOBO TECHNOLOGIES LTD. (Nasdaq: LOBO) (“LOBO” or the “Company”), an innovative electric mobility vehicles manufacturer and seller, today announced its unaudited financial results for the first half of fiscal year 2026 ended June 30, 2026. Mr. Huajian Xu, Chief Executive Officer of LOBO, commented, “We delivered encouraging progress in the first half of 2026, with total revenues increasing 20.6% year over year. Our core electric vehicles and accessories business remained resilient, generating 8.2% revenue growth, while our newly launched AI infrastructure services business contributed approximately $1.5 million in revenue and began to broaden our revenue base. “At the same time, we continued to sharpen our cost structure and improve operating efficiency, with total operating expenses...

HAMBURG, Germany and AUSTIN, Texas, Sept. 18, 2026 (GLOBE NEWSWIRE) — XCHG Limited (“XCharge” or the “Company”) (Nasdaq: XCH), a global provider in high-power EV charging solutions, today reported its unaudited financial results for the six months ended June 30, 2026. Mr. Yifei (“Simon”) Hou, Co-Chief Executive Officer of XCharge, commented, “While customer procurement timing and changes in project schedules affected the pace of revenue and deliveries in the first half of 2026, we remained focused on executing our long-term growth strategy. We made important commercial and product progress during the period. Our long-term partnership with EnBW marked a significant commercial milestone in Europe, while the introduction of the new-generation C7 and the launch of GridOne expanded our ability to address customers’ evolving charging...

Corporate Announcement no. 32/2026: Half-Year Report 1 January 2026  – 30 June 2026 Copenhagen, 18 September 2026 The Board of Directors and the Management have today discussed and approved the Half-Year Report of Ress Life Investments A/S for the period 1 January 2026 – 30 June 2026:Ress Life Investments A/S realised a net profit after tax of USD 6,655,829 for the period 1 January 2026 – 30 June 2026. The net profit for the period corresponds to a net return on equity of 3.2%, an earnings per share of USD 57.34 and an increase in net asset value of USD 83.69 per share. The period’s return was mainly driven by life expectancy updates, changes in discount rates, performance in the Legacy Portfolio, as well as the ageing of insureds and the resulting shortening of life expectancies, partly offset by administrative and staff costs. Profit...